Biogen RITUXAN — After Second Threshold Date remained flat by 0.0% to 30.0% in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from 30.0% to 30.0%. Over 2 years (FY 2023 to FY 2025), RITUXAN — After Second Threshold Date shows relatively stable performance with a 0.0% CAGR.
Signals the transition to a new phase of the partnership, which may involve higher or lower profit retention.
This metric identifies the economic terms governing a collaborative arrangement once a specific secondary performance or...
Common in complex pharmaceutical partnerships with multi-stage profit-sharing structures.
biib_segment_rituxan_after_second_threshold_date| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |